The biotechnology company Cyclezyme reports unchanged zero revenue and a larger operating loss in the second quarter, while after the end of the period the company strengthened its finances through a directed share issue. Operating result was -0.74 million kronor (-0.67).Earnings per share amounted to -0.29 kronor (-0.28)."The first half of 2026 was characterised by the continued development of Cyclezyme's enzyme technology and an increasingly clear focus on bringing the technology closer to industrial application. During the period, we made important progress together with our industrial partners, while after the end of the quarter we strengthened the company's financial position and shareholder base through a directed share issue," writes CEO Peter Falck. The company provides no forecast.Key figures, SEK millionQ2 2026Q2 2025Year-over-year changeRevenue0,000,00-Operating result-0,74-0,67-Earnings per share, kronor-0,29-0,28-